Multiple Myeloma Activities

PROGRAM CHAIR

Sandra E. Kurtin, RN, MS, AOCN®, ANP-C
Clinical Assistant Professor of Medicine
Adjunct Clinical Assistant Professor of Nursing
The University of Arizona Cancer Center • Tucson, Arizona


These educational activities are supported by educational grants from the following companies: Celgene Corporation and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Management of Newly Diagnosed Multiple Myeloma Patients

Multiple myeloma is a complex, multifarious disease. This activity will help the advanced practitioner understand the epidemiology, signs and symptoms, and work-up for newly diagnosed patients, as well as provide new insight into the underlying genomics (molecular and genomic markers) that help in the diagnosis, risk assessment, and staging/classification of multiple myeloma, and how this all impacts an individualized approach to treatment.

Posted: 9/27/2016                     Expires: 5/30/2017

Credits/Contact Hours: 0.50

You can no longer earn CE credit for this program, however, please participate in the education here:

Participate Without Claiming Credit

* This link will take you to the
Meniscus Educational Institute website.


Relapsed or Refractory Multiple Myeloma

Recent advances in the treatment of multiple myeloma have made prolonged remission possible for many patients. However, relapse remains inevitable for the majority of patients. This activity will provide the advanced practitioner with up-to-date information on monitoring for response and surveillance. In addition, the advanced practitioner will gain a deeper understanding of how clonal evolution and the mechanisms of action for various therapies impact clinical decision-making for older patients and patients with relapsed or refractory multiple myeloma.

Posted: 9/27/2016                     Expires: 5/30/2017

Credits/Contact Hours: 0.50

You can no longer earn CE credit for this program, however, please participate in the education here:

Participate Without Claiming Credit

* This link will take you to the
Meniscus Educational Institute website.


Management of Multiple Myeloma Patients Treated With Immunotherapy

In November 2015, the FDA approved three new therapies for multiple myeloma: daratumumab, ixazomib, and elotuzumab. The rapid-fire rate of new drug approvals for all cancer types makes it challenging for advanced practitioners to stay informed about clinical trial data, new therapies, new indications, mechanisms of action, and potential adverse reactions. This activity will provide an invaluable overview of new immunotherapies for patients with multiple myeloma.

Posted: 9/27/2016                     Expires: 5/30/2017

Credits/Contact Hours: 0.50

You can no longer earn CE credit for this program, however, please participate in the education here:

Participate Without Claiming Credit

* This link will take you to the
Meniscus Educational Institute website.


Adjunctive and Supportive Care in Multiple Myeloma

Patients with multiple myeloma are at risk for developing additional comorbidities, complications from the disease, and/or treatment-related comorbidities, such as thromboembolism, pathologic fractures, renal disease, neutropenia, or neuropathy. Advanced practitioners have a major role in overseeing supportive care and symptom management. Therefore, it is imperative that advanced practitioners have knowledge and expertise in this area. This activity addresses these issues, providing advanced practitioners with needed strategies necessary to provide the best patient outcomes.

Posted: 9/27/2016                     Expires: 5/30/2017

Credits/Contact Hours: 0.50

You can no longer earn CE credit for this program, however, please participate in the education here:

Participate Without Claiming Credit

* This link will take you to the
Meniscus Educational Institute website.


Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here
click me